Advertisement

Oncology

AstraZeneca will start a clinical trial to see if its cancer drug Calquence can suppress the excessive immune response COVID-19 triggers in some patients, the drugmaker said April 14.

Advertisement

Cancer patients at a hospital in Wuhan, China, were twice as likely to be diagnosed with COVID-19 as the general population, suggesting cancer patients may face a higher risk during the pandemic, according to a study published in JAMA Oncology.

Advertisement